2.3.P.8 Stability

36 months long term stability study and at least 6 months of accelerated study are planned. The stability specification is same as that used for release of the DP.

Table 2.17 Stability protocol

Testing conditions	Checkpoint (month)									
	0	**1**	**2**	**3**	**6**	**9**	**12**	**18**	**24**	**36**
Accelerated (25±2℃)	△	√	√	√	△	√√	--	--	--	--
Long-term (5±3℃)	△	--	--	√	△	√	△	√	△	△

△. Appearance, pI, SE-HPLC, WCX-HPLC, potency (binding and blocking assay), endotoxin, sterility and protein content.

√√Stability testing will continue if no significant differences in the test results were observed after 6 months.

√SE-HPLC, WCX-HPLCand protein content.

--: not tested

Nine months of stability data are available for long term storage conditions and accelerated conditions. The results indicated that the DP is stable under the long term storage conditions. In the 9 months accelerated stability testing, aggregate level trend up while monomer purity trend down when tested by SE-HPLC. When tested by WCX-HPLC Sum of acidic peak 1 and the sum of other basic peaks trend up while sum of K0+K1+K2 trend down. pI is out of specification at nine month time point. No significant changes were observed in other testing results (Tables 3.72 -3.74). The results indicated that SE-HPLC and WCX-HPLC could be stability indicating assays. The impact of such change to product quality and safety will be studied during the clinical development of KN035.